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The unexpected death of a teenager from neurocys-
ticercosis prompted an investigation of this disease in
Oregon. We found 89 hospitalizations, 43 newly diagnosed
cases, and 6 deaths from 1995 to 2000. At least five cases
occurred in persons who had not traveled or lived outside
the United States. Enhanced surveillance for neurocysticer-
cosis is warranted.
N
eurocysticercosis, an infection of the central nervous
system with the larval form of the pork tapeworm
Taenia solium, causes substantial illness and death in
developing countries. The disease has recently been
increasingly recognized as a public health problem in the
United States, primarily in southwestern states bordering
Mexico (1). In nonborder states, however, neurocysticer-
cosis may be an underrecognized problem.
In September 2000, Oregon’s Statewide Child Fatality
Review Team reviewed the unexpected death of a 17-year-
old girl due to neurocysticercosis; the diagnosis was made
postmortem. We describe this case and present the results
of the investigation of the epidemiology of neurocysticer-
cosis in Oregon that followed. 
Case Report
A previously healthy teenage girl, who had immigrated
to Oregon from Mexico as an infant, sought care in
January 2000 for progressively severe headaches of sever-
al months duration. After three office visits, “tension
headaches” were diagnosed, and symptomatic therapy was
prescribed. Neuroimaging was not performed. Several
days later she was found dead at home in her bed. Autopsy
showed no evidence of trauma, and results of a toxicology
screening were negative. Examination of the brain showed
obstructive hydrocephalus, bilateral uncal herniation, flat-
tening of the cerebral gyri, and an intact cysticercus com-
pressing the inferior 4th ventricle (Figure 1). 
The Study
We searched the Oregon Hospital Discharge Database
to identify Oregon hospitals that had discharged patients
with the ICD-9-CM code for neurocysticercosis (123.1)
from January 1995 through December 2000 and requested
the medical records of these patients. Available medical
records were abstracted by using a standardized data col-
lection instrument. We searched the Oregon death certifi-
cate database for additional neurocysticercosis deaths
during the same period. 
A case of neurocysticercosis was defined as any person
with a hospital discharge code of 123.1 or death certificate
diagnosis of neurocysticercosis during the study period,
and a record of imaging studies or pathology reports con-
sistent with neurocysticercosis. An incident case was
defined as one for which no reference to any previous
diagnosis of neurocysticercosis was found in the medical
record. Incidence rates were calculated by using U.S.
Census Bureau yearly population estimates for Oregon as
the denominator (2,3). Data were analyzed with EpiInfo,
version 6.04d (Centers for Disease Control and
Prevention, Atlanta, GA).
We found 89 hospital discharges coded for neurocys-
ticercosis during the study period among 18 hospitals in 10
counties. Medical records were made available for 76
(85%) of these hospitalizations. Review of these records
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Figure 1. A) Coronal section of brain showing dilation of ventricles,
flattening of the cerebral gyri, and uncal herniation. B) Intact cys-
ticercus occupying the 4th ventricle
A
Bconfirmed the diagnosis of neurocysticercosis for 59 per-
sons (17 were admitted more than once). Review of death
certificates showed one additional nonhospitalized case-
patient. Thus, including the death described above, we
found 61 persons who met the case definition for neuro-
cysticercosis; 43 (70%) of these were incident cases.
Figure 2 shows neurocysticercosis hospital discharges and
new diagnoses by year. The annual number of incident
cases did not change significantly during the study period.
The mean annual incidence rate from 1995 to 2000 was 0.2
per 100,000 general population and 3.1 per 100,000
Hispanic population. 
Among the 61 confirmed patients, 40 (66%) were male,
and 52 (85%) were Hispanic. The median age at the time
of first hospitalization was 24 years (range 2 to 79 years);
13 (21%) were <18 years old. Occupation was recorded for
37 adult patients. Agriculture or other manual labor was
the most common job type listed (20/37; 54%); 21%
patients were unemployed or disabled; 40% of patients had
no health insurance.
The country of birth was recorded for 57 persons. Of
these, 41 (72%) were born in Mexico, 10 (18%) in the
United States, 3 (5%) in Guatemala, and 1 (2%) each in
Korea, Saudi Arabia, and an unspecified African country.
Of the 10 neurocysticercosis patients born in the United
States, 5 had never traveled outside the United States. Four
of these five cases occurred among children (ages 3, 5, 5,
and 12 years); their source of exposure to Taenia eggs was
not documented. The source of exposure for the adult
patient was presumed to be a household contact visiting
from Mexico. Travel histories of four of the remaining
U.S.-born patients included a Caribbean cruise by a retired
pig farmer, extensive travel in Madagascar and Tanzania
by a student, annual visits to Puerto Rico by an 11-year-
old, and 1 week spent in Mexico City by a toddler. No
information about travel was documented for one patient,
a 3-year-old child. 
The median duration of hospitalization was 3 days
(range 1–30 days). Admission to an intensive care unit
occurred in 21% of hospitalizations. Treatment included
craniotomy with cyst removal (16%), ventriculoperitoneal
shunting (12%), albendazole (18%), praziquantel (19%),
anticonvulsive therapy (63%), and corticosteroids (49%). 
Five persons died in addition to the patient described
here. Two of these deaths also occurred unexpectedly
before diagnosis; both resulted from acute hydrocephalus
caused by an obstructing cyst on the 4th ventricle. Three
patients who had been previously diagnosed with neuro-
cysticercosis died. The causes of death in these patients
were aspiration pneumonia after craniotomy and cyst
removal, intracerebral hemorrhage, and hydrocephalus due
to recurrent cerebrospinal fluid shunt failure. The median
age at time of death was 33 years (range 17–73 years).
Conclusions
This study demonstrates that neurocysticercosis causes
substantial illness and death among Hispanic populations
in Oregon. Many of those affected are young immigrants
from Mexico without medical insurance, who are either
unemployed or are working in agriculture or other manual
labor. At least five cases appear to have been acquired in
the United States. Our study did not address where disease
transmission occurred for persons born outside of the
United States; some of these cases could also have been
acquired locally. 
Several previous reports have documented the increas-
ing recognition of neurocysticercosis in the United States,
but the emphasis has been primarily on disease occurring
in southwestern states bordering Mexico (4) and small out-
breaks elsewhere (5–7). Previously, the only available
information about the occurrence of neurocysticercosis in
the Pacific Northwest was a study of seizure patients at 11
university-affiliated, urban emergency departments
throughout the United States. In that study, cases were con-
centrated in southwestern states; four cases were found in
Oregon during a 2-year period (8). The study underesti-
mated the incidence of this disease in the Northwest, and
perhaps other areas of the United States, by looking for
cases only in selected urban emergency departments.
The average annual incidence of neurocysticercosis
among Oregon’s Hispanic population found in our study is
higher than that previously reported in Los Angeles
County (1.6/100,000) (9) and in Mexico (0.8/100,000)
(10). Low U.S. Census Bureau population estimates due to
undercounting of Hispanic migrants could have resulted in
a falsely elevated incidence rate. In addition, the higher
observed incidence in Oregon may have been a result of
greater case ascertainment because hospital discharge data
were used rather than physician and laboratory reports.
Nevertheless, because of our study design, we probably
underestimated the true number of incident cases. Persons
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Figure 2. Number of neurocysticercosis hospital discharges and
new diagnoses by year; Oregon, January 1995–December 2000. in outpatient clinics and emergency departments in whom
neurocysticercosis had been diagnosed (who did not
become hospitalized) were not counted in our study. We
also did not include in the analysis of cases 15% of hospi-
tal discharge diagnoses that we could not confirm by chart
review; if these had been confirmed as neurocysticercosis,
then the true number of new cases may have been even
higher. Although the Hispanic population in Oregon grew
by an estimated 67% during the study period (2,3), the
number of hospitalizations and new diagnoses did not
increase. Whether this finding represents a true decrease in
incidence or a shift in diagnosis and management of these
cases to the outpatient setting, is unclear.
Neurocysticercosis has not previously been a reportable
condition in Oregon, and no public health followup of the
patients with locally acquired cases was performed to
determine the source of these persons’exposures to Taenia
eggs. Previous serologic studies (11,12) would suggest that
these patients acquired disease from household contact
with a T. solium carrier. Early identification and public
health followup of neurocysticercosis patients may lead to
the recognition and treatment of tapeworm carriers, there-
by preventing additional cases. However, since excretion
of Taenia eggs is intermittent, direct parasitologic exami-
nation of stools is not a sensitive test (11). Collecting mul-
tiple stool samples from asymptomatic persons may also
be a challenge. A serologic test for detection of taenaisis
has been developed (13), but it is not yet commercially
available. Public health providers need simple, inexpen-
sive, and readily available techniques for rapidly identify-
ing Taenia carriers in order to conduct optimal followup of
cases and prevent additional cases. 
The World Health Organization has estimated that more
than 2 million persons are infected with adult tapeworms
(14). As a result of increasing immigration and foreign
travel,  T. solium will likely continue to emerge as an
important pathogen in the United States. Cysticercosis and
taeniasis were designated as reportable conditions in
Oregon in 2002. We hope that public health surveillance
activities will more accurately define the incidence and
risk factors for illness in Oregon, allow identification and
treatment of tapeworm carriers, and provide epidemiolog-
ic and clinical data to physicians caring for patients in at-
risk populations. 
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